Valuation: Signal Genetics Inc

Market Cap 233.27Cr 205.42Cr 194.63Cr 175.71Cr 331.16Cr 22TCr 335.44Cr 2.33TCr 896.1Cr 11TCr 875.92Cr 856.82Cr 37TCr P/E 2026 *
-5.21x
P/E 2027 * -8.04x
Enterprise Value 154.56Cr 136.1Cr 128.95Cr 116.42Cr 219.42Cr 15TCr 222.26Cr 1.54TCr 593.74Cr 7.58TCr 580.37Cr 567.71Cr 24TCr EV / Sales 2026 *
51.4x
EV / Sales 2027 * 7.83x
Free-Float
99.32%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Signal Genetics Inc

Manager TitleAgeSince
Chief Executive Officer 55 30/10/2023
Director of Finance/CFO 46 12/09/2023
Chief Tech/Sci/R&D Officer - 01/01/2024
Director TitleAgeSince
Director/Board Member 74 03/01/2018
Chairman 40 01/06/2021
Director/Board Member 51 14/07/2021
Change 5-day change 1-year change 3-year change Capi.($)
+4.16%-0.36%+49.37%+94.17% 7.45TCr
-0.19%+1.32%+37.20%+83.85% 6.01TCr
-1.51%+2.39%+9.10%+35.15% 4.82TCr
-0.05%+0.37%+41.54%+36.65% 4.43TCr
+0.38%+7.61%+339.53%+641.55% 4.4TCr
+0.18%+0.26%+7.41%+103.45% 4.16TCr
-0.67%+0.17%+7.60%+46.37% 3TCr
+4.77%+6.16%+36.77%+22.78% 2.93TCr
-1.29%-3.55%-20.74%+352.04% 2.49TCr
Average +0.64%+1.18%+56.42%+157.33% 4.41TCr
Weighted average by Cap. +0.84%+1.36%+61.05%+148.01%

Financials

2026 *2027 *
Net sales 3Cr 2.65Cr 2.51Cr 2.26Cr 4.27Cr 288.07Cr 4.32Cr 30Cr 12Cr 147.27Cr 11Cr 11Cr 472.15Cr 23Cr 21Cr 20Cr 18Cr 33Cr 2.24TCr 34Cr 233.57Cr 90Cr 1.15TCr 88Cr 86Cr 3.68TCr
Net income -46Cr -41Cr -39Cr -35Cr -66Cr -4.45TCr -67Cr -463.26Cr -178.28Cr -2.27TCr -174.26Cr -170.46Cr -7.29TCr -32Cr -28Cr -27Cr -24Cr -45Cr -3.07TCr -46Cr -319.16Cr -122.82Cr -1.57TCr -120.06Cr -117.44Cr -5.02TCr
Net Debt -79Cr -69Cr -66Cr -59Cr -111.74Cr -7.55TCr -113.18Cr -785.71Cr -302.36Cr -3.86TCr -295.55Cr -289.11Cr -12TCr -50Cr -44Cr -42Cr -38Cr -71Cr -4.81TCr -72Cr -500.35Cr -192.55Cr -2.46TCr -188.21Cr -184.11Cr -7.88TCr
Logo Signal Genetics Inc
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-